Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00948909 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety Study for Subjects With Mild-to-Moderate Alzheimer's Disease
A Phase 2 study of Alzheimers Disease, sponsored by AbbVie (prior sponsor, Abbott).
- Completed
- Registry status
- Phase 2
- Development phase
- 274
- Enrollment target
- 20
- Study locations
NCT00948909 is a Phase 2 study of Alzheimers Disease that has completed, run by AbbVie (prior sponsor, Abbott). The registered enrollment target is 274 participants, below the 4,059-participant average among 142 other Alzheimers Disease trials with a reported enrollment target (93% lower). The trial reports 20 study locations across 4 states.
The verdict
NCT00948909, a Phase 2 study of Alzheimers Disease, has completed, sponsored by AbbVie (prior sponsor, Abbott).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 274 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a efficacy and safety study evaluating new treatment for subjects with mild to moderate Alzheimer's Disease.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG ABT-126
- DRUG donepezil
Study Locations (20)
Other
- Site Reference ID/Investigator# 22944 - Pleven
- Site Reference ID/Investigator# 22942 - Plovdiv
- Site Reference ID/Investigator# 22945 - Sofia
- Site Reference ID/Investigator# 22946 - Sofia
- Site Reference ID/Investigator# 20276 - Litoměřice
- Site Reference ID/Investigator# 20273 - Pilsen
- Site Reference ID/Investigator# 20274 - Prague
- Site Reference ID/Investigator# 20272 - Prague
- Site Reference ID/Investigator# 20701 - Prague
- Site Reference ID/Investigator# 23625 - Bratislava
- Site Reference ID/Investigator# 23624 - Bratislava
- Site Reference ID/Investigator# 23622 - Michalovce
- Site Reference ID/Investigator# 23942 - Rimavská Sobota
- Site Reference ID/Investigator# 20267 - Belville
- Site Reference ID/Investigator# 20266 - Cape Town
- Site Reference ID/Investigator# 20261 - Durban
- Site Reference ID/Investigator# 21682 - George
California
- Site Reference ID/Investigator# 19904 - Fresno
Florida
- Site Reference ID/Investigator# 23025 - West Palm Beach
Indiana
- Site Reference ID/Investigator# 19905 - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 274 participants |
| Start Date | 2009-10 |
| Est. Completion | 2010-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00948909
The ClinicalTrials.gov registry entry for NCT00948909 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 274 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,059-participant average among 142 other Alzheimers Disease trials with a reported enrollment target (93% lower). The listed sponsor is AbbVie (prior sponsor, Abbott), which has 88 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Alzheimers Disease appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT00948909 reports 20 study locations spanning 4 distinct geographic areas - top geographies include Other, California, Florida.
Frequently Asked Questions
What is clinical trial NCT00948909 about?
NCT00948909 is a clinical study titled "Efficacy and Safety Study for Subjects With Mild-to-Moderate Alzheimer's Disease". This is a efficacy and safety study evaluating new treatment for subjects with mild to moderate Alzheimer's Disease.
What is the current status of trial NCT00948909?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 274 participants. The study started on 2009-10. Estimated completion is 2010-11.
What conditions does trial NCT00948909 study?
This clinical trial studies the following conditions: Alzheimers Disease.
What interventions are being tested in trial NCT00948909?
The interventions under investigation include: Placebo (DRUG), ABT-126 (DRUG), donepezil (DRUG).
Who is sponsoring clinical trial NCT00948909?
This trial is sponsored by AbbVie (prior sponsor, Abbott), which has 88 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00948909 being conducted?
This trial has 20 study locations across California, Florida, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimers Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Assessment of Foralumab Safety and Modulation of Microglial Activation in Alzheimer's Disease
RECRUITING · Phase 2
-
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
RECRUITING · Phase 2
-
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
RECRUITING · Phase 2
-
Open-label Extension Study in Participants With Early Alzheimer's Disease
RECRUITING · Phase 2
-
A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease
RECRUITING · Phase 2
-
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.